Xponance’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-18,550
| Closed | -$746K | – | 1845 |
|
|
2026
Q1 | $746K | Buy |
18,550
+386
| +2% | +$8.32K | 0.01% | 850 |
|
|
2025
Q4 | $456K | Buy |
18,164
+681
| +4% | +$16K | ﹤0.01% | 992 |
|
|
2025
Q3 | $396K | Sell |
17,483
-875
| -5% | -$20.4K | ﹤0.01% | 1049 |
|
|
2025
Q2 | $318K | Buy |
18,358
+2,261
| +14% | +$41.9K | ﹤0.01% | 1116 |
|
|
2025
Q1 | $352K | Buy |
16,097
+2,025
| +14% | +$55.9K | ﹤0.01% | 1043 |
|
|
2024
Q4 | $449K | Buy |
14,072
+749
| +6% | +$22.5K | ﹤0.01% | 981 |
|
|
2024
Q3 | $384K | Sell |
13,323
-450
| -3% | -$16.7K | ﹤0.01% | 1016 |
|
|
2024
Q2 | $528K | Buy |
13,773
+968
| +8% | +$43.8K | 0.01% | 896 |
|
|
2024
Q1 | $753K | Sell |
12,805
-122
| -0.9% | -$7.78K | 0.01% | 807 |
|
|
2023
Q4 | $774K | Sell |
12,927
-939
| -7% | -$47.6K | 0.01% | 769 |
|
|
2023
Q3 | $527K | Sell |
13,866
-181
| -1% | -$7.95K | 0.01% | 873 |
|
|
2023
Q2 | $1.28M | Buy |
14,047
+8,632
| +159% | +$745K | 0.02% | 583 |
|
|
2023
Q1 | $357K | Buy |
5,415
+46
| +0.9% | +$2.65K | 0.01% | 1002 |
|
|
2022
Q4 | $278K | Buy |
5,369
+114
| +2% | +$6.05K | ﹤0.01% | 1051 |
|
|
2022
Q3 | $359K | Buy |
5,255
+370
| +8% | +$21.9K | 0.01% | 951 |
|
|
2022
Q2 | $221K | Buy |
+4,885
| New | +$223K | ﹤0.01% | 1076 |
|
|
2021
Q3 | – | Sell |
-3,556
| Closed | -$225K | – | 1179 |
|
|
2021
Q2 | $225K | Buy |
+3,556
| New | +$183K | ﹤0.01% | 1143 |
|
Other funds holding APLS
Xponance's APLS Position: Q2 2026 in Review
Xponance sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 18,550 shares — an estimated $746K sold.
Xponance first reported a position in APLS in Q2 2021 and held it in 17 quarters. The position peaked at $1.28M in Q2 2023. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Xponance reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Xponance sold 18,550 Apellis Pharmaceuticals shares in Q2 2026, an estimated $746K.
- Xponance first reported a position in Apellis Pharmaceuticals in Q2 2021 and held it in 17 quarters.
- Xponance's Apellis Pharmaceuticals position peaked at $1.28M in Q2 2023.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.